$TVGN News

Tevogen Bio Holdings Q1 EPS $(1.61) Beats $(2.50) Estimate

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen Enters $3M Private Placement PIPE Financing At $8.00/Prefunded Warrant, Issuing 375K Warrants Each Exercisable For The Purchase Of 1 Share Of The Company's Common Stock

Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Bio Eyes Acquisition Of Global CRO To Add $20M+ Revenue And Fuel Growth Across Oncology, Rare Diseases, And Medical Devices

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen Bio Regains Nasdaq Compliance

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Tevogen Reports Advanced Performance For Its AI Platform; Recent Testing Of PredicTcell Model Shows Recall Enhancement From 87% To 92%, Improved Precision From 40% To 48%

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

Tevogen Names Leadership Team to Execute Diversified Growth Strategy

Tevogen Names Leadership Team For Diversified Growth Strategy Targeting Additional $50M In Annual Revenue By Q2 2026 End

Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen Bio Explores Buyout To Boost Generics Platform

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical